Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional activity is important for developing new AR-targeted therapies. FOXA1 is a key component of the AR transcriptional complex yet its role in prostate cancer progression and the relationship between AR and FOXA1 are not completely resolved. It is well established that FOXA1 levels are elevated in advanced prostate cancer and metastases. We mimicked these conditions by overexpressing FOXA1 in the androgen-responsive LNCaP prostate cancer cell line and observed a significant increase in AR genomic binding at novel regions that possess increased chromatin accessibility. High levels of FOXA1 resulted in increased proliferation at both sub-optimal and high 5a-dihydrotestosterone (DHT) concentrations. Immunohistochemical staining for FOXA1 in a clinical prostate cancer cohort revealed that high FOXA1 expression is associated with shorter time to biochemical recurrence after radical prostatectomy (hazard ratio (HR) 5.0, 95% confidence interval (CI) 1.2-21.1, P ¼ 0.028), positive surgical margins and higher stage disease at diagnosis. The gene expression program that results from FOXA1 overexpression is enriched for PTEN, Wnt and other pathways typically represented in CRPC gene signatures. Together, these results suggest that in an androgen-depleted state, elevated levels of FOXA1 enhance AR binding at genomic regions not normally occupied by AR, which in turn facilitates prostate cancer cell growth.
INTRODUCTION
Prostate cancer is the most common non-cutaneous cancer in men accounting for almost one-third of all newly diagnosed cancers. 1 The standard first line of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT), which typically induces regression of the tumor. Despite a high initial response rate in nearly all cases, resistance to ADT occurs resulting in tumor regrowth which is termed as castration-resistant prostate cancer (CRPC). 2 Tumors that become resistant to ADT pose a significant clinical challenge. The development of new hormonal therapies that target androgen biosynthesis (for example, Abiraterone) or the androgen receptor (AR) directly (for example, Enzalutamide) has produced improved outcomes for patients with CRPC, but they are not universally effective and responses are not durable. 3, 4 The AR remains active and critical for tumor growth in CRPC despite low circulating levels of androgens, but typically there are alterations in the receptor structure or function that allow it to retain activity despite ADT. Documented methods for circumvention of ADT include AR gene amplification, acquisition of mutations, genomic rearrangements and alternative splicing of AR. 2, [5] [6] [7] [8] An additional mechanism is altered interaction of AR with key transcriptional cofactors. 9 The forkhead transcription factor FOXA1 is a key member of the AR transcriptional complex, which has been shown to interact directly with AR through the hinge domain. 10 FOXA1 functions primarily as a pioneer factor, binding to closed chromatin regions through its winged helix domain, which has a structure akin to that of linker histones. FOXA1 association with chromatin contributes to changes in chromatin accessibility, rendering these regions more accessible to nuclear receptors such as AR, 11 estrogen receptor 12 and progesterone receptor. 13 As such, FOXA1 has a key role in demarcating the tissue-specific binding sites of these nuclear receptors.
14 FOXA1, expressed in the peripheral zone of the human prostate, 15 is essential for hormone induced ductal branching and epithelial cell maturation of the prostate gland during puberty. 16 Furthermore, FOXA1 has a central role in AR-driven gene expression in both the normal prostate and prostate cancers. 11, 17, 18 There are a number of conflicting reports regarding the role that FOXA1 has in the progression of prostate cancer to castrateresistant disease and its expression has been associated with both good and poor prostate cancer patient outcome. One study suggested that FOXA1 mRNA levels are moderately upregulated in primary cancer when compared with benign disease, but unexpectedly it was downregulated in metastasis. 19 In contrast to this observation, a number of immunohistochemical studies have shown that FOXA1 is a marker of poor outcome in prostate cancer, with high FOXA1 levels being associated with a shorter time to biochemical recurrence (BCR) 15, 20 or prostate cancer-specific death.
21 High expression at the protein level has also been noted in the majority (82-89%) of metastatic and CRPC samples.
At the molecular level, it remains to be determined what the exact consequences of higher FOXA1 levels are for prostate cancer progression. Examination of AR binding events in CRPC cell line models and primary tissues suggests that the unique CRPC AR sites are not reliant upon FOXA1 23, 24 and similarly, FOXA1 may have AR-independent functions in CRPC. 25 Despite this, FOXA1 overexpressing LNCaP prostate cancer cells exhibit increased migration and produce larger tumors in xenograft models. 15, 26 Thus, it is imperative to assess the consequences of elevated FOXA1 expression and the potential impact on AR signalling during prostate cancer progression.
In this study, we assessed the downstream effects of elevated FOXA1 levels on AR chromatin binding, gene expression and prostate cancer cell proliferation. We found that in cells expressing higher levels of FOXA1, AR makes novel chromatin associations and is able to drive tumor cell growth even at reduced levels of androgen, suggesting that tumors with higher FOXA1 levels may have a growth advantage following androgen deprivation.
RESULTS
Higher levels of FOXA1 result in increased AR binding Given the disputed role that elevated levels of FOXA1 play in prostate cancer, we aimed to examine the effects of overexpression of FOXA1 in prostate cancer cells. The LNCaP prostate cancer cell line was transiently transfected with a control vector or an FOXA1 construct, which we subsequently termed as 'FOXA1 high' cells. Western blot analysis confirmed increased FOXA1 levels compared with GFP control-transfected cells (Supplementary Figure 1A) . Since AR is central to both primary and castrate-resistant prostate cancer, we initially focused on the effect of increased levels of FOXA1 upon AR binding. Genomewide AR binding regions were mapped in asynchronous 'FOXA1 high' versus GFP control cells and we found an almost two-fold increase in reproducible AR binding sites (ARBSs) in 'FOXA1 high' cells (33 953 ARBSs in control cells versus 57 155 ARBSs in 'FOXA1 high' cells; Supplementary Table 1 ). The majority (86%) of the ARBS in control cells were also seen in FOXA1 high cells. However, under elevated FOXA1 conditions, an additional 28 100 ARBS were observed (Figure 1a) .
In general, there was a significant increase (Po0.0001) in AR peak strength across all sites in 'FOXA1 high' cells compared with control ( Figure 1b) . Shared regions identified in both control and FOXA1 overexpressing cells have a significantly higher mean read count at the AR peak summit in 'FOXA1 high' cells (8.34 reads) compared with control (6.03 reads; Figure 1c) . Additionally, there are a large number of sites (28 100) where an ARBS was only detected in 'FOXA1 high' cells, termed as 'gained' sites ( Figure 1c) . Interestingly, the new ARBSs that occur in the presence of elevated FOXA1 are regions that have some weak binding in control cells, implying an amplification of AR-DNA binding at Figure 1c ). Overall, our data suggest a general amplification of AR binding in the presence of higher FOXA1 levels as illustrated by a heatmap of the shared and gained ARBS (Figure 1d ) and an example genomic region (Figure 1e ). This phenomenon was confirmed in another ARdriven cancer cell line model, the ERa-AR þ MDA-MB-453 cell line, which is used as a model of molecular apocrine breast cancer. AR chromatin immunoprecipitation coupled to high-throughput sequencing (ChIP-seq) in 'FOXA1 high' MDA-MB-453 cells also showed greater AR binding intensity than in control cells ( Supplementary Figure 2A and Figure 1B and C).
Increase in AR occupancy after FOXA1 overexpression is likely due to increased chromatin accessibility To infer the mechanism behind the increased AR binding seen after FOXA1 overexpression, we assessed whether there was a global increase in AR protein levels, but we did not detect an appreciable change in AR levels following FOXA1 overexpression (Supplementary Figure 1A) . Therefore to identify alternate factors that may be redirecting AR to the chromatin, we conducted de novo motif analysis on the unique ARBS associated with FOXA1 overexpression. We found a significant enrichment for motifs representing STAT3, SP1 and the ETS (ELF5) transcription factors ( Figure 2a) . We also detected a strong enrichment for forkhead motifs suggesting a large majority of the new ARBS may be directed by FOXA1 itself. Comparison of our data with the previously published LNCaP FOXA1 ChIP-seq data 27 revealed that FOXA1 is present at a large number (37%) of the gained ARBSs ( Figure 2b ). Therefore, overexpression of FOXA1 may directly mediate AR binding to 'FOXA1 high' gained regions. This is supported by the visible but relatively weak FOXA1 binding at these gained AR binding regions, which one could postulate is increased upon FOXA1 overexpression (Supplementary Figure 3) .
In an effort to identify additional regulatory mechanisms that impinge on the AR-FOXA1 complex, we performed RIME (Rapid IMmunoprecipitation of Endogenous proteins) proteomic analysis 28 of each transcription factor. Three independent replicates of AR and two independent replicates of FOXA1 RIME were conducted. Proteins must have been detected in at least two replicates, but in none of the matched IgG control immunoprecipitations to be considered as an interacting protein. This led to the identification of 139 AR and 236 FOXA1 interacting proteins (Supplementary Table 2 ). In total, 56 proteins interact with both AR and FOXA1 in our data. Pathway analysis of these common interacting partners revealed a highly significant enrichment for proteins involved in chromatin remodelling, in particular for the locus control region-associated remodelling complex (Figure 2c ; Supplementary Table 2) . Locus control region-associated remodelling complex is a complex that controls accessibility of regulatory DNA sequences situated many kilobases away from their cognate promoters 29 that AR and FOXA1 co-occupy. A number of these proteins have been validated in other studies to interact with AR. [30] [31] [32] [33] FOXA1's intrinsic pioneer factor function coupled to its interaction with a large number of histone modifying enzymes suggests that increased binding of AR under FOXA1 high conditions may occur because of enhanced chromatin accessibility at these regions.
FOXA1 overexpression increases proliferation in AR-driven cancers and correlates with poor outcome in prostate cancer The effect of high levels of FOXA1 on prostate cancer proliferation was assessed in AR þ LNCaP prostate cancer cells and our second AR-driven cancer model, the MDA-MB-453 molecular apocrine breast cancer cell line. Western blot analysis confirmed FOXA1 overexpression in MDA-MB-453 cells with no alteration in AR protein levels (Supplementary Figure 1A) . Proliferation of both cell lines was assessed following treatment with either high (100 nM 5a-dihydrotestosterone, DHT) or low (0.5 nM DHT) androgen concentrations, the latter to mimic androgen-depleted conditions observed following ADT. 'FOXA1 high' cells exhibited significantly higher levels of proliferation than GFP control-transfected cells at both DHT concentrations (Figure 3a) . Interestingly, a similar effect of FOXA1 overexpression was observed in the MDA-MB-453 breast cancer cells following treatment with high and low doses of androgen (Figure 3b ), suggesting that higher expression of FOXA1 enhances the growth promoting effects of AR in a ubiquitous, non-tissue specific manner in AR-driven cancers.
To address some of the conflicting data regarding the prognostic value of FOXA1 expression in prostate cancer, we undertook an immunohistochemical analysis of FOXA1 in a tissue microarray (TMA) of 102 prostate cancer cases. Our study with a median follow-up time of 86 months after radical prostatectomy (range 3-151 months) has longer follow-up than other published studies. Examples of FOXA1 immunostaining in prostate cancer are shown in Figures 4a-f. We found FOXA1 expression to be significantly higher in tumors compared with matched benign and normal prostate tissues (median H-score cancer ¼ 69.44 versus benign ¼ 0, P-valueo0.0001; Supplementary Figure 4) .
In evaluating the association between FOXA1 H-score and BCR, we divided patients into two groups based on the first quartile given that this cut point showed the most significant difference. There was a significantly higher risk of BCR for patients with high FOXA1 staining (H-score 44.0, second through fourth quartile) compared with those with no or low FOXA1 staining, H-score p4.0 (hazard ratio (HR) 5.0, 95% confidence interval 1.2-21.1, P ¼ 0.028; Figure 4g ). In particular, we noted a marked difference in the 10-year BCR-free survival rate; 94.1% (95% confidence interval 83.6-100%) for patients with low FOXA1 staining compared with 53.6% (95% confidence interval 42.2-68.0%) for those with high FOXA1 staining. As detailed in Table 1 , high FOXA1 staining also significantly correlated with higher pathological stage (Po0.0001) and positive surgical margins (P ¼ 0.021), which are markers of poor disease outcome (Supplementary Table 3 ). There was no statistically significant evidence of an association with Gleason Score (P ¼ 0.25). Additionally, we assessed whether FOXA1 predicted outcome independently of other known prostate cancer markers. We observed a greater than threefold increased risk of BCR in patients with high FOXA1 staining compared with those with low staining when adjusting individually for pathological stage (HR: 3.60, P ¼ 0.084, n ¼ 79), Gleason Score (HR: 3.02, P ¼ 0.13, n ¼ 74) and prostate specific antigen (PSA) (HR: 4.58, P ¼ 0.039, n ¼ 76), although this was not always significant in these smaller samples with missing clinicopathologic data. (Figure 5a ). The majority of these genes have an ARBS within 25 kb of their start site in 'FOXA1 high' cells (93/124 differentially regulated genes, 75%) implying that AR may be directly regulating expression of these differential genes. However, these genes are not typically regulated in vitro by DHT in the context of normal endogenous levels of FOXA1, with only 5.6% of the differentially expressed genes in 'FOXA1 high' cells considered to be androgen regulated in an independent data set of DHT-treated LNCaP cells. 34 Pathway analysis of the 'FOXA1 high' differentially expressed genes (Figure 5b ) revealed a number of networks focused on signalling pathways known to be perturbed in prostate cancer (PTEN null, polycomb targets and TNC targets that signal through WNT) as well as differentiation pathways (Trogatizalone targets, poorly differentiated carcinoma and mature luminal cell program). Due to the high expression of FOXA1 in CRPC and metastases, 15, 22 we used Gene Set Enrichment Analysis to correlate the CRPC gene program identified by Sharma et al 24 from primary CRPC tissue with the data from our 'FOXA1 high' microarray. There was a significant enrichment of the CRPC gene set in our data set (P-value 0.018, normalized enrichment score 1.14; Figure 5c ) implying that FOXA1 may be in part responsible for the expression of a number of the genes expressed in CRPC. In support of this concept, others have shown that silencing of FOXA1 in LNCaP-abl cells (one model of CRPC) has both AR-dependent and -independent effects on cell proliferation, 25 and that loss of FOXA1 inhibits ligand-dependent AR chromatin binding in C4-2B cells (another LNCaP-derived model of CRPC). 23 Importantly, we found that silencing of FOXA1 in C4-2B cells markedly inhibited their proliferative capacity (Supplementary Figure 5) . Our data suggest that high levels of FOXA1 can drive a overexpression of FOXA1. The simplest hypothesis for this difference is that in the absence of FOXA1, alternative transcription factors mediate AR binding to chromatin. In the presence of FOXA1, relative levels of this pioneer factor appear to be the rate-limiting determinant of AR chromatin binding in prostate cancer cells. Under conditions where FOXA1 is abnormally elevated, AR gains the capacity for enhanced chromatin binding at non-classical sites, as observed in CRPC. Intriguingly, these alterations in AR and FOXA1 binding elicit a gene expression program that is reminiscent of that seen in CRPC primary tissues, which also exhibit high FOXA1 expression. 15, 22 Resistance to ADT and progression to CRPC involves a diverse range of adaptive mechanisms to enhance AR signalling. 4 Herein, we provide evidence that one such mechanism could be via upregulation of FOXA1, resulting in an expanded AR chromatin binding landscape. Tumors with high FOXA1 levels may have greater intrinsic AR activity and therefore are better adapted to survive at low levels of androgen. The increased proliferation that 'FOXA1 high' cells exhibited with low androgen concentrations in our study supports this theory. Further in vivo investigation of the effect of increased FOXA1 levels on tumor growth is required. To date, two reports have been published investigating the effects of high FOXA1 levels on tumor growth, but the conclusions were inconclusive. The first of these studies concluded that elevated FOXA1 inhibits prostate cancer metastasis in an orthotopic mouse xenograft model. 19 However, in that study, the AR-negative PC3-M cell line, which is not representative of the vast majority of prostate tumors, including CRPC, was used as the experimental model. Another xenograft study that examined the consequence of FOXA1 overexpression in AR þ LNCaP cells found a significant increase in tumor size compared with parental control cell xenografts, 26 consistent with the results of the current study.
FOXA1 has been implicated as a marker of poor outcome in a number of tumor types, including lung, 35 thyroid, 36 esophageal 37 and malignant glioma. 38 Our data support the growing bank of evidence suggesting that FOXA1 is a marker of poor outcome in prostate cancer patients, where high expression levels correlate with a shorter time to biochemical relapse. 15, 20, 22, 39 Furthermore, high FOXA1 expression robustly correlates with higher pathological stage, higher Gleason Score and AR expression, 15, 20, 21 implying a central role for FOXA1 in the progression of prostate cancer. In contrast, high FOXA1 mRNA levels correlate with better patient outcome measures, such as a longer time to BCR. 10, 19 A study of the concordance between changes seen by mRNA microarray analysis and of high-throughput proteomic profiling of primary prostate cancer tissue showed only a 48-61% agreement. 40 Given the role of FOXA1 as a transcription factor that modulates chromatin accessibility and binding of other proteins, it is prudent to consider the correlations that occur with protein levels rather than mRNA levels.
The exact role that FOXA1 plays in CRPC is still unclear, but interestingly it was recently observed that FOXA1 is mutated in 3-5% of prostate cancers, suggesting that altered FOXA1 function may be a feature of CRPC. 26, 41 Some in vitro data suggest that FOXA1 may not have an important part of the AR transcriptional complex in CRPC. Unique castration-resistant ARBS detected in the C4-2B cell line 23 does not significantly overlap with FOXA1 binding sites or contain the Forkhead motif. However, our results show that ablating FOXA1 in the C4-2B cell line robustly diminishes cell growth, indicating a persistent role for FOXA1. Additionally, our gene expression data for FOXA1 overexpressing LNCaP cells correlated well with a published CRPC gene signature, 24 indicating that FOXA1 may be an important player in the switch to a more aggressive gene expression profile like that seen in CRPC. Thus, it will be critical to map AR and FOXA1 binding in matched primary and CRPC tissues to definitively assess the role of FOXA1 in prostate cancer progression.
In summary, FOXA1 is a key component of the AR transcription factor complex. High levels of FOXA1 result in increased AR binding, a transcription profile akin to CRPC and proliferation in the presence of low levels of androgenic hormones. These findings suggest a pivotal role for FOXA1 in the progression of prostate cancer.
MATERIALS AND METHODS

Cell culture and transfection
LNCaP and C4-2B prostate cancer and MDA-MB-453 breast cancer cell lines were grown in RPMI or DMEM media, respectively, supplemented with 10% FBS and standard antibiotics. For hormone deprivation conditions, phenol red-free RPMI or DMEM medium was supplemented with 5% charcoal dextran-treated FBS. Cells were transfected with 3 mg FOXA1 expression plasmid per 10 cm dish using Lipofectamine 2000 (Invitrogen, Paisley, UK), according to the manufacturer's instructions. Full-length FOXA1 cDNA was ligated into pcDNA3.1. Chromatin immunoprecipitation coupled to high-throughput sequencing AR ChIP experiments were conducted as described previously 43 using rabbit polyclonal anti-AR antibody (Santa Cruz Biotechnologies; sc-816). Briefly, 48 h after transfection with GFP or FOXA1 expression plasmid cells were crosslinked with 1% formaldehyde and harvested. Cells were lysed, nucleus extracted and DNA sonicated using a Biorupter (Diagenode, Bois Saint-Jean, Belgium) before immunoprecipitation with AR antibodyconjugated beads. Beads were thoroughly washed and reverse crosslinked at 65 1C before amplification using the TruSeq kit (Illumina, San Diego, CA, USA). Single-end 36-bp ChIP-seq data were generated by the Illumina analysis pipeline version 1.6.1 (Illumina), and reads were aligned to the Human Reference Genome (assembly hg19, GRCh37, February 2009) using bwa 0.5.9. Reads with MapQ scores o16 or falling within Duke's Excluded Regions 44 were filtered from further analysis. Peaks were called using MACS, version 1.4.1. Heatmaps were created using python script as described in Ross-Innes et al. 45 For all ChIP-seq experiments, two biological replicates were performed and only reproducible peaks (that is, those that occur in both replicates) were considered in downstream analysis if it is occurred in both replicates. Motif analysis was performed using MEME-ChIP suite. 46 Hierarchical clustering analysis of peaksets was performed using the DiffBind package (version 1.4.2) in Bioconductor version 2.11. 47 
Rapid IMmunoprecipitation of Endogenous proteins
LNCaP cells were crosslinked with 1% EM-grade formaldehyde for 7 min before they were harvested. RIME experiments were conducted as described in Mohammed et al. 28 Antibodies used for immunoprecipitation were anti-AR (sc-816), anti-rabbit IgG (sc-2027) and anti-goat IgG (sc-2028) FOXA1 enhances AR function in prostate cancer JLL Robinson et al from Santa Cruz Biotechnologies and anti-FOXA1 (ab5089) from Abcam. Mass spectrometry was performed using LTQ Orbitrap Velos (Thermo Scientific). Raw MS data files were processed using Proteome Discoverer v.1.3 (Thermo Scientific). Processed files were searched against the SwissProt human database using the Mascot search engine version 2.3.0, allowing up to one tryptic miscleavage and a tolerance on mass measurement of 10 p.p.m. in MS mode and 0.6 Da for MS/MS ions. Identified proteins have at least two unique peptides and not occurred in any of the matched IgG samples. Pathway analysis of the common AR and FOXA1 partners was performed using GSEA molecular signature database tool version 3.1 48 and STRING (version 9.05) produced the protein interaction network. 49 
Microarray analysis
Cells were transfected with GFP or FOXA1 expression plasmid for 48 h. RNA was collected from six biological replicates. The Illumina BeadChIP (HumanWG-12 version 4) bead-level data were preprocessed, log2-transformed and quantile-normalized using the bead array package 50, 51 in Bioconductor. 52 Differential expression analysis was performed using limma eBayes (Smyth 2004 with a Benjamini and Hochberg multiple test correction procedure) 53 to identify statistically significant differentially expressed genes (False Discovery Rate 0.05). GSEA molecular signature database tool version 3.1 48 was used for pathway analysis of differentially expressed genes. (43) were also taken as well as prostatic intraepithelial neoplasia where available. 54 We define BCR as a single prostate specific antigen value of X0.2 ng/ml, with persistent elevation on subsequent prostate specific antigen measurement. We included a 'triggered treatment' group where the decision to initiate treatment with modalities such as radiotherapy occurred before the prostate specific antigen value had reached this threshold. Time to relapse was calculated as the time from radical prostatectomy to first prostate specific antigen of 0.2 ng/ml or treatment, whichever occurred first.
Patient cohort
Immunohistochemistry
Paraffin-embedded TMA blocks were freshly cut before immunohistochemistry that was performed on a Bond automated system (Leica, Milton Keynes, UK). Primary goat anti-FOXA1 antibody (Abcam, ab5089), dilution 1:800 in Sanger diluent, was used with the F DABe protocol and Bond epitope retrieval solution 1 for 20 min. Evaluation of the stained TMAs was undertaken by two independent observers, one of which was a specialized uropathologist (AW). Analysis was conducted using a multi-headed microscope and neither had any knowledge or information pertaining to the patient's clinical status. Staining intensity for FOXA1 was evaluated on a four-tiered scale: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong) as well as the percentage of nuclei stained. The resultant H-score incorporates both pieces of data (H-score ¼ intensity Â % positive stained cells).
Statistical analysis
To compare the difference in H-score between tumor and matched normal/benign, the Wilcoxon matched-pairs signed rank test was performed. To assess the effect of FOXA1 expression on prostate cancer patient outcome, patients were divided into groups based on quartiles of their FOXA1 H-score, quartiles 2-4 were combined for analysis. The Kaplan-Meier method was used to estimate the proportion of patients free of BCR after radical prostatectomy, censoring at the last date of follow-up. A univariable Cox proportional hazards regression model was used to evaluate the association between FOXA1 staining and time to relapse. Clinical and pathological information was compared with FOXA1 staining using either a Mann-Whitney test for continuous data or Fisher's exact test for categorical data.
Wilcoxon matched-pair signed rank test was used to assess of the significance in the average read count for AR ChIP-seq samples in control and 'FOXA1 high' cells. All other analyses unless stated were performed using unpaired Student's T-Test or Fisher's exact test. Only values with a P-value of o0.05 were considered as significant. Statistical analyses were performed using the R Statistical software (version 2.14.0) or Graphpad Prism 6.
Data deposition
ChIP-seq sequencing data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under the accession number E-MTAB-1749. Microarray data have been deposited in the GEO database (accession number is pending).
ABBREVIATIONS
ADT, androgen deprivation therapy; AR, androgen receptor; ARBS, androgen receptor binding site; ChIP, chromatin immunoprecipitation; CRPC, castrate-resistant prostate cancer; DEG, differentially regulated genes; DHT, 5a-dihydrotestosterone; RIME, rapid immunoprecipitation of endogenous proteins.
